The tumor suppressor TP53 is one of the most frequently mutated and malfunctioned genes in the pathological process of LC, and its genetic and functional status may serve as a predictor for the risk, survival, and therapeutic outcomes of LC [59–63]. The gene discussed is TP53; the disease is laryngotracheoesophageal cleft.